Genolution Inc is a Korea-based company principally engaged in the manufacture and distribution of molecular diagnostic equipment and products related to ribonucleic acid interference (RNAi) research. The Company is mainly engaged in the manufacture and sales of nucleic acid extraction reagents for extracting nucleic acids from human samples and automated nucleic acid extraction devices for automatically extracting nucleic acids from samples. The Company also provides RNAi services. The Company distributes its products within domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	₩1,116.00	+1.36%	101,352
26-06-25	₩1,101.00	+6.89%	156,427
26-06-24	₩1,030.00	-10.82%	853,789
26-06-23	₩1,155.00	-5.48%	84,746
26-06-22	₩1,222.00	-10.80%	149,167

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-06-26			5-day change	1st Jan Change
1,116.00 ^KRW	+1.36%		-18.54%	-41.23%

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI

Market Cap	20.16B 13.15M 11.53M 10.63M 9.95M 18.65M 1.24B 19.04M 128M 49.42M 613M 49.37M 48.29M 2.13B	P/E 2024	-5.89x	P/E 2025	-2.95x
Enterprise Value	16.28B 10.61M 9.31M 8.58M 8.03M 15.06M 1B 15.37M 103M 39.89M 495M 39.85M 38.98M 1.72B	EV / Sales 2024	4.38x	EV / Sales 2025	3.23x
Free-Float	67.36%	Yield 2024 *	-	Yield 2025	-

02-18	Kim Ki-ok completed the acquisition of 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd.	CI
01-20	Kim Ki-ok agreed to acquire 4.22% stake in Genolution Inc. from HoilBioMed Co., Ltd for KRW 1.5 billion.	CI
24-07-30	Genolution Inc. cancelled the transaction announced on May 7, 2024	CI
24-05-06	Genolution Inc. announced that it expects to receive CNY 750.00284 million in funding from RICO Asset Management Co., Ltd. and another investor	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-09	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
24-01-08	Genolution Inc.'s Equity Buyback announced on July 10, 2023, has expired with 477,003 shares, representing 2.59% for KRW 1,989.17 million.	CI
23-10-13	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023.	CI
23-07-10	Genolution Inc. announces an Equity Buyback for KRW 2,000 million worth of its shares.	CI
23-07-09	Genolution Inc. authorizes a Buyback Plan.	CI
23-05-15	Genolution Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI
23-04-05	Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on October 6, 2022.	CI

1 day	+1.36%
1 week	-18.54%
Current month	-33.81%
1 month	-38.10%
3 months	-38.24%
6 months	-42.15%
Current year	-41.23%

Genolution Inc. Stock

Stocks

A225220

KR7225220003

Biotechnology & Medical Research

Valuation: Genolution Inc.

Chart: Genolution Inc.

Latest news : Genolution Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Genolution Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	957	1,458
1 month	957	1,802
Current year	957	2,120
1 year	957	2,830
3 years	957	5,140
5 years	957	10,891.09
10 years	957	13,118.81

Manager	Title	Age	Since
Min-Ee Kim CEO	Chief Executive Officer	40	-
Ki-Ok Kim CEO	Chief Executive Officer	71	2006-01-31
Sang-Hoon Kim DFI	Director of Finance/CFO	66	-

Director	Title	Age	Since
Ki-Ok Kim BRD	Director/Board Member	71	2006-01-31
Hak-Soo Lee BRD	Director/Board Member	70	2020-03-19
Min-Ee Kim BRD	Director/Board Member	40	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-05-23	Sang-Hoon Kim	Others	Chief Financial Officer	404,000	2.1053%
24-05-18	Sang-Hoon Kim	Free	Chief Financial Officer	404,000	2.1053%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GENOLUTION INC.	+1.36%	-18.54%	-52.81%	-73.99%	13.15M
VERACYTE, INC.	+3.31%	+12.79%	+125.62%	+136.10%	4.83B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	+3.51%	+19.57%	+72.37%	+211.44%	3.35B
BGI GENOMICS CO., LTD.	-4.54%	-2.42%	-29.54%	-42.23%	1.96B
IOVANCE BIOTHERAPEUTICS, INC.	+0.95%	+8.70%	+144.25%	-43.56%	1.9B
CAREDX, INC.	+3.48%	+10.08%	+49.40%	+243.10%	1.49B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+1.63%	+19.62%	+161.34%	-51.44%	917M
SEEGENE, INC.	-3.95%	+0.72%	-17.77%	+32.08%	842M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-1.09%	-7.70%	-37.99%	-21.09%	466M
CURIOX BIOSYSTEMS CO., LTD	-8.07%	-26.89%	-0.39%	-	435M
Average	-0.34%	+3.26%	+41.45%	+43.38%	1.62B
Weighted average by Cap.	+1.24%	+9.70%	+77.37%	+97.19%

	2024	2025
Net sales	7.14B 4.65M 4.08M 3.76M 3.52M 6.6M 439M 6.74M 45.2M 17.49M 217M 17.47M 17.09M 752M	9.4B 6.13M 5.38M 4.96M 4.64M 8.7M 578M 8.88M 59.57M 23.05M 286M 23.03M 22.52M 991M
Net income	-6.83B -4.45M -3.9M -3.6M -3.37M -6.31M -420M -6.45M -43.23M -16.73M -207M -16.71M -16.35M -719M	-11.64B -7.59M -6.66M -6.14M -5.74M -10.77M -716M -10.99M -73.74M -28.54M -354M -28.51M -27.88M -1.23B
Net Debt	-8.95B -5.84M -5.12M -4.72M -4.42M -8.28M -550M -8.45M -56.69M -21.93M -272M -21.91M -21.43M -943M	-3.89B -2.53M -2.22M -2.05M -1.92M -3.59M -239M -3.67M -24.61M -9.52M -118M -9.51M -9.31M -410M